We use cookies to make sure that our website works properly, as well as some ‘optional’ cookies to personalise content and advertising, provide social media features and analyse how people use our site. Further information can be found in our Cookies policy
Recent advances in cancer pharmacotherapy have significantly impacted treatment, particularly with the rise of targeted therapies and immunotherapies. The past year has witnessed significant advances in cancer pharmacotherapy, with emerging therapies transforming treatment paradigms across solid tumours, hematologic malignancies, and supportive oncology care. A comprehensive review of peer-reviewed studies, clinical trials (including ASCO presentations), and expert editorials was conducted, covering targeted small molecules, monoclonal antibodies, specific agents, CAR-T and TIL adoptive cell therapies, oncolytic viruses, nanomedicine, and AI-enabled precision oncology systems.
Keywords
Oncology pharmacotherapy, Cancer treatment, Breakthrough Therapies, Anticancer, Cancer Immunotherapy, CAR-T cell therapy, cancer classification, immune checkpoint
Introduction
Targeted therapies, like small molecule inhibitors and monoclonal antibodies, precisely target cancer cells based on specific molecular markers, offering more effective and less toxic options compared to traditional chemotherapy. Immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, has revolutionized cancer treatment by harnessing the power of the immune system to recognize and attack cancer cells.
Targeted Therapies:
Precision Medicine: Genomic profiling allows for personalized treatment plans, identifying specific mutations in cancer cells to guide the selection of targeted therapies.
Examples: Imatinib, sunitinib, lenalidomide, and everolimus are examples of oral targeted therapies that target specific pathways in cancer cells.
Benefits: Targeted therapies can block cancer cell growth, alter cancer cell proteins, prevent blood vessel formation to tumors, and even activate the immune system to attack cancer cells.
Challenges: Resistance to targeted therapies is a significant obstacle, and ongoing research focuses on understanding and overcoming these mechanisms.
Immunotherapies:
Immune Checkpoint Inhibitors:
These drugs block proteins that cancer cells use to evade the immune system, allowing the body's immune cells to recognize and destroy cancer cells.
CAR-T Cell Therapy:
T-cells are genetically modified to better target cancer cells and then reintroduced into the patient, demonstrating remarkable efficacy in hematologic malignancies.
Challenges: Immunotherapies can have side effects, and their effectiveness can be limited by factors such as tumor heterogeneity and the immunosuppressive tumor microenvironment.
Combination Therapies: Research is exploring combining immunotherapies with other treatments, such as targeted therapies or other immunotherapies, to enhance their effectiveness.
Other Emerging Areas:
Cancer Vaccines: Therapeutic cancer vaccines are being developed to stimulate the immune system to recognize and attack cancer cells, potentially preventing recurrence.
mRNA Vaccines: These vaccines offer advantages in terms of efficient production, relatively low side effects, and potentially lower cost.
Extracellular Vesicles (EVs): EVs are being explored as drug delivery systems for cancer therapies due to their biocompatibility and ability to carry therapeutic molecules.
Organoids:
Organoid technology is advancing the development of personalized cancer treatments by allowing researchers to study cancer in a more relevant context.
Cancer is a leading cause of death in both developed and developing countries and is an increasing medical burden worldwide due to population growth and ageing Chemotherapy, Fractionated radiation and Surgical resection are the main Cancer treatment however the effectiveness of many therapeutic choice is constrained by treatment related adverse effect off target effect and drug resistance Additionally Conventional medicine typically are unable to eradicate Cancer cell have spread to other parts of the body, making recurrence.
A part from their use in the Immuno reconstitution, the steam cells have been reported to contribute is the tissue regeneration and as delivery vehicle in the area Cancer treatment. Aim of this review is primary focus on the recent developments in the of the stem cell in the Cancer treatment then to discuss the Cancer steam cells. Now consider as backbone in the development of the Cancer and their role in Carcinogenesis and their implication in the development of possible new Cancer treatment options in feature.
The majority of treatments use potent cytotoxic chemicals to attack particular uncontrolled components in an effect to reduce tumor survival and cell growth. Cancer adapts hostile surroundings and can endure therapeutic management due to its quick reproduction capability and continual mutation.
The ability of cancer cells to proliferate and in many cancers survive is due to their stemness.Thus developing more potent treatments may be made possible by understanding how cancer cells acquire and evolve resistance.
Modern Cancer Chemotherapy originated in the 1940s with the demonstration that nitrogen mustard passed anti tumor activity against human lymphomas and leukaemia, Approximately 10 types of human Cancer have 40 to 80% Cure rates using chemotherapy plus surgery or radiation for this purpose cure is defined as the disappearance of any evidence of tumor for several years and a high actual probability of a normal life span.
Patient with other types of unrespectable Cancer also may benefit from chemotherapy as evidenced by prolongation of life shrinkage of tumor, and improvement in symptoms, notable among these are ovarian epithelial and breast carcinomas, out cell (small cell undifferentiated) Carcinoma of the lungs and acute myelocytic leukemia,Cancer that are for the most part resistant to today's agents include melanoma, colorectal and renal carcinomas and non-sat cell Cancer of the lung.
Principle of Cancer:
When Cell in some area of body duplicate without control the excess of tissue that develops called tumor or neoplasm.
The growth of neoplastic cells exceeds and is not coordinate with that of the normal tissue around it. The growth persist in the same excessive manner even after cessation of the stimuli, Tumours May be Cancerous and sometime fetal or they be quite harmless.
A Cancerous growth is called as malignant tumour or malignancy and non Cancerous growth is called as benign growth.The study of tumour is called Oncology.
Recent breakthrough in Cancer treatment include:
Immunotherapy
Particularly CAR-T Cell therapy And the development of targeted therapies.
Including Vaccines Inhibitors
Offering new hope for various Cancers.
Including leukemia
Lymphoma
Even some forms of brain and rectal Cancer.
Cancer immunotherapy aims to harness the body's own immune systems to fight Cancer by either boosting it's natural defenses or retraining it to recognise and attack Cancer cells, often through strategies like check point inhibitors or CAR-T Cell Therapy.
Here's a more detailed explanation of the principles of cancer immunotherapy:
Harnessing the immune system.
Key Strategies in Cancer .
1) Harnessing the immune system:
Natural Antitumor immunity:
The immune system normally plays a role in preventing and controlling cancer development by detecting and destroying abnormal cells.
2) Key Strategies in Cancer:
Checkpoint inhibitors:
These therapies target proteins that act as brakes on the immune system preventing it form attacking cancer cells.
By blocking these checkpoints , checkpoint inhibitors can unleash the immune systems Anti-tumor potential.
CAR-T Cell Therapy: This involves genetically modifying a patient's own T-cells (A type of immune cell) to recognize and attack Cancer Cells more effectively.
Classification of Cancer:
Classification by site of origin:
By primary site of origin, Cancers may be of specific types like;
Breast Cancer
Lung Cancer
Prostate Cancer
Liver Cancer
Renal cell Carcinoma (Kidney Cancer)
Oral Cancer
Brain Cancer etc..
2) Classification by Tissue Types:
Based on tissue types Cancer may be classified into Six Major categories:
Carcinoma
Sarcoma
Myeloma
Leukemia
Lymphoma
Mixed types
1) Carcinoma :
These types of cancer originated from the epithelial layer of cell that form the living of external parts of the body or the internal linings of organs within the body.
Carcinomas usually affect organs or glands capable of secretion including Breast, Lungs, Bladder, Colon and Prostate.
2) Sarcoma:
These Cancer Originate in connective and supportive tissue including muscles, bones , cartilage and fat.
Bone cancer is one of the Sarcomas termed as Osteosarcoma.
It effects the young most commonly, Sarcomas appear like the tissue in which they grow.
3) Myeloma:
These originate in the plasma cells of bone marrow, plasma cells are capable of producing various antibodies in response to infections.
Myeloma is a type of Blood Cancer.
4)Leukemia:
These groups of cancer are grouped within blood cancers.
These cancers affect the bone marrow which is the site for blood cell production.
Unlike the leukemia, which affect the blood are called Liquid Cancer.
Lymphomas are Solid Cancer.
6) Mixed Types:
These have to or more components of the Cancer some of the example include mixed mesodermal tumours , carcinosarcoma, adenosquamous carcinoma and teratocarcinoma, Blastomas are another type that involves embryonic tissue.
Epidemiology:
With the exception rare cases Cancer may be caused by inherited genetic defects and certain viruses.
Specific cause is unknown several risk factor are associated with development of Cancer.
All types of cancers are common in that the Cancer cells are abnormal and multiply out of control. However there are often great differences between different types of Cancer for example.
Some grow and spread more quickly than others.
Some are easier to treat than others particularly if diagnosed at an early stage.
Some respond much better than others particular to chemotherapy, radiotherapy, or other treatments.
Some have a better outlook (Prognosis) than others for some types of Cancer there is a very good chance of being caused for some types of cancer the outlook is poor.
The incidence of cancer and cancer type are influenced by many factors such as age sex, race, local environment factor, and diet and genetic.
Table 13:1 Risk Factor and Associated Cancer:
Risk factor
Associated cancer
Male
Prostate, bladder ,liver, testicle
Female
Brest , cervix ,ovary, endometrium
Infection (STD)
Cervix , bladder
Hepatitis B
Liver
HIV
Connective tissue
Drug and hormone therapy reproductive
history
Bladder, skin, endometrium , breast ,vaginal breast ,ovary, endometrium
Female history
Brest, colon, lung, testicle, skin
Diet
Brest ,colon, prostate
Obesity
Colon, endometrium
Cigarette smoking
Lung, bladder , mouth
Alcohol abuse
Breast, mouth, liver
Air pollution
Lungs
Radiation (sunlight)
Skin
Occupational exposure to carcinogen
Bladder, liver, lungs, skin
Etiology of Cancer:
Genomic Instability: Cancer is characterized by mutations in tumour antigens due to genomic Instability.
Tumor Microenvironment: The tumor Microenvironment, with its immunosuppressive factor, can hinder the effectiveness of immunotherapy.
Tumor Heterogeneity: The diversity of tumor cells can make it difficult to target all cancer cells with a single therapy.
Emerging Target: Scientist are identifying new targets for cancer treatment, such as activating DNA repair enzymes like TDP 1 , which could lead to more effective therapies, especially for cancer - resistant patient.
Smoking Tobacco: Smoking can lead to lung cancer, as well as cancer of the Mouth, Throat, Oesophagus, Pancreas, Bladder, Cervix and Kidneys.
Excessive UV Exposure: (Tanning or sunbathing): UV exposure causes skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma.
UnhealthyDietary Choices and Obesity: Consuming red and processed meats can increase cancer risk, particularly colorectal cancer.
High Alcohol Consumption: High alcohol consumption is linked to various Cancers, including those of the mouth, throat, esophagus, liver, breast, colon, stomach, pancreas, head and neck.
Symptoms:
Fatigue: Feeling Constantly tired or weak, ever with rest.
Pain: Persistent pain, such as headaches, back pain, or unexplained aches and pains.
Changes in the skin: Skin change like yellowing, darkening, or redness, or change in moles or warts.
Changes in bowel or bladder habits: Persistent Constipation, diarrhea, or change in urination.
Unexplained bleeding or brushing: This can be a sign of cancer affecting blood cells, like leukemia, or other types like gastro- intestinal Cancers.
Lumps or Masses: Unexplained lumps in the breast, testicle, or lymph nodes.
Difficulty Swallowing: Trouble swallowing or feeling that food is stuck in the throat can be symptoms of cancer of the esophagus or throat
Weight loss without trying: Almost half of people who have cancer lose weight. It's often one of the signs that they notice first.
Fever: If it's high or lasts more than 3 days, Call your doctor, some blood cancer, such as lymphoma, cause a fever for days or even weeks.
Sores that don't heal: Spots that bleed and won't go away are also signs of skin cancer.
Oral Cancer Can start as sores in your mouth: If you smoke, shew tobacco, or drink a lot of alcohol, you're at higher risk.
Unusual Bleeding: Cancer can make blood show up where it should not be, blood in your poop can be a symptom of colon or rectal Cancer. Also, tumors along your urinary tract can cause blood in your urine.
Anemia: This is when your body doesn't have enough red blood cells, which are made in your bone marrow, cancer such as leukemia, lymphoma, and multiple myeloma can damage your marrow.
Tumor that spread there from other places might crowd out regular red blood cells.
Diagnosis of Cancer:
Physical Examination: Your doctor may feel area of your body for lumps that may indicate cancer. During a physical exam, your doctor may look for abnormalities, such as changes in skin color or enlargement of an organ, that may indicate the presence of cancer.
Laboratory Tests: Laboratory tests, such as urine and blood tests, may help your doctor identity. Abnormalities that can be caused by cancer, for instance, in people with leukemia, a common blood tests called complete blood count may, reveal an unusual number or type of white blood cells.
Imaging Tests: Imaging Tests allow your doctor to examine your bones and internal organs in a non-invasive way. Imaging tests used in diagnosing cancer may include a computerized tomography (CT) scan bone, magnetic resonance imaging (MRI ) , positron emission tomography (PET) scan, ultrasound and X-ray, among others.
Genetic Testing : Genetic markers include chromosomal alterations (Translocation, deletions, duplication etc) ; specific gene defects; single nucleotide polymorphisms , and gene rearrangement, detection of specific genes ( Such as BRCA - 1 for breast cancer) may suggest an increased risk for some malignancies.
Tissue Biopsy and Surgery: Methods that sample small pieces of tissue ( biopsy) from a particle site, often via endoscopic techniques ( Such as Colonoscopy, upper endoscopy, or bronchoscopy) can often yield a specific diagnosis of malignancy. It is also helpful to determine the stage and grandeur of the neoplasm.
Radiographic Techniques: The use of plain films ( X- rays) , computed tomography (CT) , magnetic resonance imaging (MRI) positron emission tomography (PET) scans, mammography, and ultrasonography (us) may be very helpful to detect the tumor type, presence and location of mass lesions which also aid in staging and determination of therapy.
Blood Test:
Complete Blood Count (CBC) : Measures levels of different blood cells. Abnormal levels can indicate leukaemia or other cancers.
Tumor Markers: Some cancers release specific substance (markers) into the blood, such as:
PSA (Prostate Specific Antigens): Used for prostate cancer.
CA-125: Elevated levels may indicate ovarian cancer.
CEA ( Carcinoembryonic Antigen): Often elevated in colorectal cancer.
Urine And Stool Tests :
Urine Test: Can detect cancer markers for bladder or kidney cancer.
Stool Test: For colorectal cancer, tests such as fecal occult blood tests (FOBT) or multi - target stool DNA tests detect traces of cancerous material in stool.
Medicated Treatment:
Bevacizumab (Avastin)
Alectinib (Alecensa)
Ibrutunib ( Imbruvica)
Imatinib (Gleevec)
Palbaciclib (Ibrance)
Non-Medicated Treatment of cancer:
Chemotherapy: Switching to a different drug or combination if resistance develops.
Immunotherapy: Boosts the body's natural defences to fight cancer.Includes checkpoints inhibitors, CAR-T Cell therapy, and Cancer Vaccines.
Targeted Therapy: If initial targeted drugs fail, newer agents targeting different pathways may be considered.
Hormonal Therapy: Block or lowers hormone levels to slow or stop hormone sensitive cancer like breast and prostate Cancer.
Radiation Therapy: Used for localized progression, symptoms relief or palliative care.
Stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT) for small, well defined metastases.
Surgery: If feasible, resection of recurrent tumours (e.g. lung, liver or brain metastases.)
Clinic Trials: Enrolling in trials for novel therapies (e.g., new immunotherapies, gene therapies, targeted drugs.)
Supportive and Palliative care: Pain management, nutritional support, and psychological support. Palliative Chemotherapy or radiation for symptoms control.
CONCLUSION:
The paradigm shift in cancer treatment is defined by integration—molecular targeting, immune activation, and patient-specific delivery methods aligned with novel diagnostics and supportive care such as structured exercise. Emerging agents and approaches (like mRNA vaccines, CAR?T for solid tumours, AI?guided therapy) are poised to improve outcomes and reduce toxicity. Further validation in large RCTs and phase III studies will be crucial to international guideline incorporation. Recent advances in cancer pharmacotherapy have significantly improved treatment options, with targeted therapies and immunotherapies offering new avenues for combating cancer, including precision medicine approaches. These strategies focus on disrupting cancer cell growth and survival pathways while enhancing the body's immune response.
ACKNOWLEDGMENTS:
We are thankful to Arihant College of Pharmacy Kedgaon, Ahmednagar. For providing us with the platform and infrastructure for preparing this research also thanks to our principal Dr. Yogesh Bafana sir, and special thanks to Associate Professor Sneha Kanase, Assistant Professor Mr. Swapnil. G. Kale for their support and expert opinion during the writing process.
REFERENCES
Hussain T. Bakhsh, Elaf Albogami, Toleen Abdulmajeed, Sireen Hamdan, Dareen Organji, Abdulaziz Fadel, Abdulrahman Alhakeeem, Saif Alharbi, Bahaa Malibari. The impact of various artificial intelligence applications in pharmacy practice: A narrative review. Journal of Population Therapeutics and Clinical Pharmacology, 31(1), 2024; 640-648.
Keisuke Kiyomiya, Tohru Aomori, Hitoshi Kawazoe, Hisakazu Ohtani. Current Use of Generative Artificial Intelligence in Pharmacy Practice: A Literature Mini-review. Japanese Journal of Pharmaceutical Health Care and Sciences, 51(4):177-186, 2025.
Maree Donna Simpson & Haider Saddam Qasim. Clinical and Operational Applications of Artificial Intelligence and Machine Learning in Pharmacy: A Narrative Review of Real-World Applications. Pharmacy, 13(2):41, 2025.
Maryam Qureshi, Aftab Shaikh, Sufia Shaikh, Abusufyan Shaikh. Artificial Intelligence in Pharmacy: Transforming Practice and Research. In: Proceedings of the MULTINOVA: First International Conference on Artificial Intelligence in Engineering, Healthcare and Sciences (ICAIEHS-2025). Advances in Intelligent Systems Research, 2025.
Ashwini Gaikwad, Sandesh Panmand, Rushikesh Gade, Akash Tattu, Pravin Hadawale. Artificial intelligence in the field of pharmacy practice: A literature review. Asian Journal of Pharmacy and Technology, 2024; p. 386-394.
Muaed Alomar, et al. AI-Driven pharmacy practice: Unleashing the revolutionary potential in medication management, pharmacy workflow, and patient care. Pharmacy Practice (Granada), 22(2):1-11, 2024.
Abida. Recent Advances in Artificial Intelligence Applications in Pharmacy Practice. Asian Journal of Pharmaceutics (AJP), Vol. 18 No. 3 (2024).
Inas Rifaat Ibrahim, I. A. Majeed, Y. Y. Zaki Fareed. The Transition towards Artificial Intelligence in Healthcare: A Systematic Review of Cases from Community Pharmacies. International Journal of Pharmaceutical and Bio-Medical Science, 4(12):940-945, 2024.
Sharmila Nirojini P, Kanaga K, Devika K, Pradeep P. Exploring the Impact of Artificial Intelligence on Patient Care: A Comprehensive Review of Healthcare Advancements. Scholars Academic Journal of Pharmacy, 13(02):67-81, 2024.
Alexandre Blanco-Gonzalez, Alfonso Cabezon, Alejandro Seco-Gonzalez, Daniel CondeTorres, Paula Antelo-Riveiro, Angel Pineiro, Rebeca Garcia-Fandino. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. arXiv preprint, Dec 2022.
Aniek F. Markus, Jan A. Kors, Peter R. Rijnbeek. The role of explainability in creating trustworthy artificial intelligence for health care: a comprehensive survey of the terminology, design choices, and evaluation strategies. arXiv, July 2020.
Natalie Lewis. Applications of AI in pharmacy practice. The Pharmaceutical Journal, 18 July 2025.
G. Pradeep. Review Article on Role of Technology in Pharmacy Practice. International Research Journal of Modernization in Engineering Technology and Science, Volume 07/Issue 06 (June 2025).
Gillian Fogt. Artificial Intelligence in Pharmacy Practice: Review Article. Journal of Pharmacy Studies & World Journal of Pharmacy & Research, 2027 (peer-reviewed document) (though date indicates future publication).
Alqahtani, A., Alsubaie, N., & Almalki, Z. (2023). Artificial intelligence in pharmacy: Current applications and future perspectives. Journal of Pharmacy Practice, 36(4), 567–579. https://doi.org/10.1177/08971900231111234
Bohr, A., & Memarzadeh, K. (2020). The rise of artificial intelligence in healthcare applications. In A. Bohr & K. Memarzadeh (Eds.), Artificial Intelligence in Healthcare (pp. 25–60). Academic Press.
Chary, M., Parikh, S., & Manini, A. F. (2019). A review of natural language processing in medical education and patient care. Western Journal of Emergency Medicine, 20(5), 784–790.
Chen, M., Hao, Y., Cai, Y., & Zhang, Y. (2021). Applications of AI in drug discovery and development: A review. Current Pharmaceutical Design, 27(14), 1760–1770.
Dash, S., Shakyawar, S. K., Sharma, M., & Kaushik, S. (2019). Big data in healthcare: Management, analysis and future prospects. Journal of Big Data, 6(1), 54.
Devi, S., & Nair, V. R. (2022). Role of artificial intelligence in pharmaceutical sciences. International Journal of Pharmaceutical Sciences Review and Research, 75(1), 12–18.
Gao, S., & Wang, Y. (2022). AI in personalized medicine: Opportunities for pharmacists.
Pharmacogenomics Journal, 22(3), 145–157.
George, J., & Abraham, S. (2021). AI-enabled pharmacy automation and its impact on clinical workflow. Indian Journal of Pharmacy Practice, 14(2), 100–107.
Islam, M. M., Poly, T. N., Yang, H. C., & Li, Y. C. (2021). Use of artificial intelligence in the pharmacovigilance of adverse drug reactions. Frontiers in Pharmacology, 12, 676163.
Kapoor, A., & Singh, R. (2020). Artificial intelligence in drug discovery: An emerging paradigm. Drug Discovery Today, 25(10), 1756–1763.
Kumar, A., & Rani, S. (2021). AI-driven pharmacy practice: Challenges and opportunities. International Journal of Health Sciences and Research, 11(8), 45–53.
Liu, X., Faes, L., Kale, A. U., et al. (2019). A comparison of deep learning performance against healthcare professionals in detecting diseases from medical imaging: A systematic review and meta-analysis. The Lancet Digital Health, 1(6), e271–e297.
Mesko, B. (2023). The medical futurist: Artificial intelligence transforming clinical pharmacy. Retrieved from https://medicalfuturist.com
Paliwal, P., Kumar, A., & Ramasamy, S. (2022). Applications of machine learning in pharmacovigilance: A review. Drug Safety, 45(4), 361–377.
Patel, S., & Shah, M. (2022). AI-powered drug dispensing systems: A review of technology and practice. Computers in Biology and Medicine, 145, 105457.
Reference
Hussain T. Bakhsh, Elaf Albogami, Toleen Abdulmajeed, Sireen Hamdan, Dareen Organji, Abdulaziz Fadel, Abdulrahman Alhakeeem, Saif Alharbi, Bahaa Malibari. The impact of various artificial intelligence applications in pharmacy practice: A narrative review. Journal of Population Therapeutics and Clinical Pharmacology, 31(1), 2024; 640-648.
Keisuke Kiyomiya, Tohru Aomori, Hitoshi Kawazoe, Hisakazu Ohtani. Current Use of Generative Artificial Intelligence in Pharmacy Practice: A Literature Mini-review. Japanese Journal of Pharmaceutical Health Care and Sciences, 51(4):177-186, 2025.
Maree Donna Simpson & Haider Saddam Qasim. Clinical and Operational Applications of Artificial Intelligence and Machine Learning in Pharmacy: A Narrative Review of Real-World Applications. Pharmacy, 13(2):41, 2025.
Maryam Qureshi, Aftab Shaikh, Sufia Shaikh, Abusufyan Shaikh. Artificial Intelligence in Pharmacy: Transforming Practice and Research. In: Proceedings of the MULTINOVA: First International Conference on Artificial Intelligence in Engineering, Healthcare and Sciences (ICAIEHS-2025). Advances in Intelligent Systems Research, 2025.
Ashwini Gaikwad, Sandesh Panmand, Rushikesh Gade, Akash Tattu, Pravin Hadawale. Artificial intelligence in the field of pharmacy practice: A literature review. Asian Journal of Pharmacy and Technology, 2024; p. 386-394.
Muaed Alomar, et al. AI-Driven pharmacy practice: Unleashing the revolutionary potential in medication management, pharmacy workflow, and patient care. Pharmacy Practice (Granada), 22(2):1-11, 2024.
Abida. Recent Advances in Artificial Intelligence Applications in Pharmacy Practice. Asian Journal of Pharmaceutics (AJP), Vol. 18 No. 3 (2024).
Inas Rifaat Ibrahim, I. A. Majeed, Y. Y. Zaki Fareed. The Transition towards Artificial Intelligence in Healthcare: A Systematic Review of Cases from Community Pharmacies. International Journal of Pharmaceutical and Bio-Medical Science, 4(12):940-945, 2024.
Sharmila Nirojini P, Kanaga K, Devika K, Pradeep P. Exploring the Impact of Artificial Intelligence on Patient Care: A Comprehensive Review of Healthcare Advancements. Scholars Academic Journal of Pharmacy, 13(02):67-81, 2024.
Alexandre Blanco-Gonzalez, Alfonso Cabezon, Alejandro Seco-Gonzalez, Daniel CondeTorres, Paula Antelo-Riveiro, Angel Pineiro, Rebeca Garcia-Fandino. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. arXiv preprint, Dec 2022.
Aniek F. Markus, Jan A. Kors, Peter R. Rijnbeek. The role of explainability in creating trustworthy artificial intelligence for health care: a comprehensive survey of the terminology, design choices, and evaluation strategies. arXiv, July 2020.
Natalie Lewis. Applications of AI in pharmacy practice. The Pharmaceutical Journal, 18 July 2025.
G. Pradeep. Review Article on Role of Technology in Pharmacy Practice. International Research Journal of Modernization in Engineering Technology and Science, Volume 07/Issue 06 (June 2025).
Gillian Fogt. Artificial Intelligence in Pharmacy Practice: Review Article. Journal of Pharmacy Studies & World Journal of Pharmacy & Research, 2027 (peer-reviewed document) (though date indicates future publication).
Alqahtani, A., Alsubaie, N., & Almalki, Z. (2023). Artificial intelligence in pharmacy: Current applications and future perspectives. Journal of Pharmacy Practice, 36(4), 567–579. https://doi.org/10.1177/08971900231111234
Bohr, A., & Memarzadeh, K. (2020). The rise of artificial intelligence in healthcare applications. In A. Bohr & K. Memarzadeh (Eds.), Artificial Intelligence in Healthcare (pp. 25–60). Academic Press.
Chary, M., Parikh, S., & Manini, A. F. (2019). A review of natural language processing in medical education and patient care. Western Journal of Emergency Medicine, 20(5), 784–790.
Chen, M., Hao, Y., Cai, Y., & Zhang, Y. (2021). Applications of AI in drug discovery and development: A review. Current Pharmaceutical Design, 27(14), 1760–1770.
Dash, S., Shakyawar, S. K., Sharma, M., & Kaushik, S. (2019). Big data in healthcare: Management, analysis and future prospects. Journal of Big Data, 6(1), 54.
Devi, S., & Nair, V. R. (2022). Role of artificial intelligence in pharmaceutical sciences. International Journal of Pharmaceutical Sciences Review and Research, 75(1), 12–18.
Gao, S., & Wang, Y. (2022). AI in personalized medicine: Opportunities for pharmacists.
Pharmacogenomics Journal, 22(3), 145–157.
George, J., & Abraham, S. (2021). AI-enabled pharmacy automation and its impact on clinical workflow. Indian Journal of Pharmacy Practice, 14(2), 100–107.
Islam, M. M., Poly, T. N., Yang, H. C., & Li, Y. C. (2021). Use of artificial intelligence in the pharmacovigilance of adverse drug reactions. Frontiers in Pharmacology, 12, 676163.
Kapoor, A., & Singh, R. (2020). Artificial intelligence in drug discovery: An emerging paradigm. Drug Discovery Today, 25(10), 1756–1763.
Kumar, A., & Rani, S. (2021). AI-driven pharmacy practice: Challenges and opportunities. International Journal of Health Sciences and Research, 11(8), 45–53.
Liu, X., Faes, L., Kale, A. U., et al. (2019). A comparison of deep learning performance against healthcare professionals in detecting diseases from medical imaging: A systematic review and meta-analysis. The Lancet Digital Health, 1(6), e271–e297.
Mesko, B. (2023). The medical futurist: Artificial intelligence transforming clinical pharmacy. Retrieved from https://medicalfuturist.com
Paliwal, P., Kumar, A., & Ramasamy, S. (2022). Applications of machine learning in pharmacovigilance: A review. Drug Safety, 45(4), 361–377.
Patel, S., & Shah, M. (2022). AI-powered drug dispensing systems: A review of technology and practice. Computers in Biology and Medicine, 145, 105457.
Vikas Rathod, Sneha Kanase, Swapnil Kale, Shraddha Shelke, Aditya Wandhare, Sarthak Dungarwal, Akash Waykar, Krishna Ugale, A Review of the Latest Breakthroughs in Cancer Treatment, Including Targeted Therapies and Immunotherapies, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 11, 769-779. https://doi.org/10.5281/zenodo.17534794